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 Background 
 Cytokine removal using the extracorporeal blood puri-
fication technique has been expected to improve the out-
comes of critically ill patients, especially in those with sep-
sis. Elevation in cytokine levels is observed in severe con-
ditions, and significantly associated with poor outcomes 
 [1] . The effect of cytokine removal by blood purification 
has been investigated using the interventions of extremely 
high volume hemofiltration (HVHF) for enhanced con-
vective clearance, and high cut-off (HCO) membranes for 
enhanced diffusive clearance. Randomized controlled tri-
als of HVHF show decreases in cytokine levels but no mor-
tality benefit  [2, 3] . There is preliminary experience with 
HCO membranes, with reported improvements of hemo-
dynamic parameters and oxygenation  [4] .
 Adsorption is another blood-purification strategy to 
remove middle-range molecules, including cytokines. 
Polymethylmethacrylate (PMMA) and polyacrylonitrile 
(PAN) membranes are known to have high adsorption 
capability  [5] . Nakada et al. [6] reported that continuous 
renal replacement therapy (CRRT) with PMMA mem-
brane showed a rapid decline of blood interleukin (IL)-6 
levels in 43 septic shock patients together with improve-
ment of hemodynamics and hyperlactemia. PAN mem-
brane such as AN69 can also remove cytokines, mainly by 
the mechanism of adsorption  [7] . The membrane is neg-
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 Abstract 
 Background/Aims: Polyethylenimine-coated polyacryloni-
trile (AN69ST) membrane is expected to improve the out-
comes of critically ill patients treated by continuous renal 
replacement therapy (CRRT).  Methods: Using a Japanese 
health insurance claim database, we identified adult pa-
tients receiving CRRT in intensive care units (ICUs) from April 
2014 to October 2015. We used a multivariable logistic re-
gression model to assess in-hospital mortality and Fine and 
Gray’s proportional subhazards model to assess the ICU 
length of stay (ICU-LOS) accounting for the competing risks. 
 Results: Of 2,469 ICU patients, 156 were treated by AN69ST 
membrane. Crude in-hospital mortality was 50.0% in the AN-
69ST group and 54.0% in the non-AN69ST group. Adjusted 
odds ratio (OR) of AN69ST membrane use for in-hospital 
mortality was 0.65 (95% CI 0.45–0.93). The use of AN69ST 
membrane was also independently associated with shorter 
ICU-LOS.  Conclusion: This retrospective observational study 
suggested that CRRT with AN69ST membrane might be as-
sociated with better in-hospital outcomes.  
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atively charged from methallylsulfonate, adsorbing cyto-
kines via ionic bonding between sulfonate groups and 
amino groups on cytokines. Newly developed polyethyl-
enimine-coated AN69ST has a hydrogel structure, which 
enables adsorption not only on the membrane surface but 
also within the bulk layer, thereby exhibiting an increased 
capacity for cytokine removal. However, like HVHF and 
HCO membranes, there is only limited evidence that this 
intervention improves outcomes in critically ill patients.
 The aim of this study is to investigate whether 
 AN69ST-CRRT is associated with lower hospital mortal-
ity and intensive care unit (ICU) length of stay (ICU-
LOS) in critically ill patients. Since 2014, the use of 
 AN69ST membrane has been approved by the National 
Health Insurance System in Japan for severe sepsis in ad-
dition to acute kidney injury (AKI) or end-stage renal dis-
ease. We analyzed claims of critically ill patients who were 
treated by CRRT admitted from April 2014 to October 
2015, and evaluated the impact of AN69ST-CRRT on 
outcomes with adjustment for potential confounders.
 Materials and Methods 
 Study Design 
 We performed an observational retrospective cohort study 
comparing AN69ST-CRRT with standard-CRRT, using an “as-
treated” framework (“did exposure that the patient actually re-
ceives affect outcomes?”)  [8] . The data were sourced from Medi-
cal Data Vision Co., Ltd (https://www.mdv.co.jp), and contains 
Japanese diagnosis-procedure combination (DPC) codes and 
health insurance claims data (irrespective of insurer). Data are 
extracted directly from electronic information systems of hospi-
tal participating in the data-sharing networks (177 hospitals, 
consisting of 21 hospitals with <200 beds; 110 hospitals with 200–
499 beds; and 46 hospitals with  ≥ 500 beds). Medical Data Vision 
Co., Ltd is a well-established data source for epidemiological and 
pharmacoeconomic studies from that country  [9–21] . Medical 
Data Vision Co., Ltd collects data only from consenting hospitals, 
and these data are de-identified at source with guaranteed ano-
nymity.
 Patient Selection and Data Source 
 We used a hospital-based composite database purchased by Bax-
ter Japan, Ltd. (Tokyo, Japan). The source data contained informa-
tion from patient admissions from April 1, 2014 to October 30, 2015. 
From this database, we identified patients treated with CRRT de-
fined by the existence of either a CRRT hemofilter claim or a CRRT 
technical fee claim record. We extracted information on identified 
patients about their age, gender, diagnosis, DPC codes, Internation-
al Classification of Diseases 10th version (ICD10) codes, surgical 
procedure, outpatient/inpatient status, drug claim record, ICU 
management fee, and renal replacement therapy history.
 We analyzed clinical data from all patients satisfying the 
 following inclusion criteria: (i) receiving CRRT; (ii) age at base-
line  ≥ 18 years. Exclusion criteria were (i) on maintenance dialysis 
as defined by pre-admission claims or chronic kidney disease at 
admission by ICD10 code; (ii) ICU-LOS greater than 60 days con-
sistent with other studies  [22, 23] . Patients were followed until they 
were discharged from the hospital.
 Variables 
 The primary endpoint was in-hospital mortality. The second-
ary outcome was the length of ICU stay (ICU-LOS). In case of 
multiple ICU admissions (different admissions defined by a gap in 
ICU technical fee records of 3 or more days), only the first admis-
sion was modeled and the rest were excluded.
 The primary exposure was the type of CRRT, dichotomized to 
AN69ST-CRRT at any time during the ICU admission versus stan-
dard-only-CRRT. The patients in the standard-only-CRRT group 
were treated with the hemofilter membranes of polysulfone, cel-
lulose triacetate, and PMMA but not with AN69ST. In case of mul-
tiple continuous sessions of CRRT (consecutive sessions defined 
by a gap in CRRT technical fee or CRRT hemofilter claim records 
of 3 or more days), only the first session was taken and the rest were 
excluded.
 We included the following covariates in models: patient age at 
admission; gender; recorded diagnoses of sepsis, disseminated in-
travascular coagulation (DIC), and AKI; modified Charlson Co-
morbidity Index (CCI) calculated from pre- or at-admission 
ICD10 codes  [24–26] ; presence and type of surgery (open abdom-
inal surgery, open cardiac surgery, non-invasive abdominal sur-
gery); emergency versus elective surgery; emergency versus elec-
tive hospital admission; number of vasopressors at first hemofilter 
use; mechanical ventilation at first hemofilter use; administration 
of blood products between hospital and first hemofilter use; ad-
ministration of albumin between ICU admission and first hemo-
filter use; hospital size; hospital DPC classification (DPC I, uni-
versity hospital; DPC II, tertiary hospital; DPC III, other acute 
care hospital); and year of admission. The specific definitions of 
these covariates and the details of their data mapping and abstrac-
tion from source datasets are provided in online supplementary 
Appendix 1 (see www. karger.com/doi/10.1159/000476052).
 Statistical Analysis 
 We constructed 3 multivariable time-varying exposure-out-
come models to estimate the effect of the type of CRRT membranes 
on the outcomes. In all the multivariable models, we initially in-
cluded all covariates in the models, which we then removed in a 
backward stepwise fashion beginning with the covariate with the 
highest  p value from 2-tailed Wald tests of the individual coeffi-
cients. We based the final confounder selection upon both bio-
logical plausibility and contribution to the comprehensibility of 
the model, and also the significance of the covariate within the 
model as assessed by the 2-tailed partial likelihood ratio test  p val-
ue at a level of 0.2 when jointly adjusted for other covariates  [27] .
 For the primary outcome of in-hospital mortality, we used lo-
gistic regression. For the secondary outcome of ICU-LOS, we used 
2 approaches. First, we used generalized linear modeling assuming 
a gamma distribution of ICU-LOS utilizing a log link, adjusting for 
ICU mortality as a measure of illness severity  [28–30] . Because ICU 
death is a competing risk to ICU discharge, we also used competing 
risks regression based on the Fine and Gray’s proportional subhaz-
ards model, modeling ICU-LOS accounting for the competing out-
come of ICU death  [31] . Subhazard ratios (SHRs) calculated using 
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this approach can be interpreted as actual rather than actuarial 
probabilities: time to “ICU discharge without death” accounting 
for the risk of “death at ICU discharge”  [32] .
 We used 2-way interaction terms in all the main-effects models 
to test effect modification by sepsis and AKI. We chose these in-
teractions as being clinically plausible, on the basis of both pub-
lished literature as well as cumulative clinical experience  [33, 34] . 
Interactions were assessed using the 2-tailed Wald test  p values as 
a guide to selecting interaction terms for testing, with significance 
within the model using the likelihood ratio test ( p value <0.05). 
Where necessary, we made comparisons between groups using the 
Fisher’s exact test and Mann–Whitney U (or Kruskal–Wallis) tests 
as appropriate.
 The claim dataset does not include a number of factors that are 
therefore not included in this study (e.g., physiological measures 
such as blood pressure, process measures such as antibiotic levels 
etc.), which might confound the relationship between hemofilter 
and outcomes. We therefore performed sensitivity analyses to es-
timate the extent to which bias due to unmeasured, hence uncon-
trolled, confounding may have over- or underestimated the true 
effect  [35–38] . We varied the prevalence of the unmeasured con-
founder among patients on standard-only-CRRT (reference 
group) and those treated with AN69ST-CRRT (comparator 
group), as well as the strength of the association between the un-
measured confounder and mortality risk reflecting various plau-
sible scenarios.
 Analyses were performed using Stata Intercooled MP/14.1 
(StataCorp, www.stata.com).
 Results 
 Participants 
 We identified a cohort of 2,469 adult patients with suf-
ficient data for modeling, with 19,494 patient-ICU-days. 
Due to the de-identified nature of the data, we were not 
able to ascertain how many hospitals (out of the 177 par-
ticipating hospitals in the Medical Data Vision’s database) 
contributed information about patients to this dataset.
 Descriptive Data 
 The mean (SD) age of all patients was 70.4 (14.2) years, 
1,643 (66.3%) of whom were males. The mean (SD) CCI 
was 2.3 (2.1). Associated sepsis diagnosis was recorded in 
1,196 (48.3%) patients, DIC in 1,166 (47.1%) and AKI in 
1,935 (78.1%). Of the cohort, 156 (6.3%) received 
 AN69ST-CRRT and 2,322 (93.7%) standard-only-CRRT. 
Consistent with the results of other investigators, the pa-
tients in our cohort had a high probability of ICU death 
(659 patients, 26.6%) and hospital death (1,331 patients, 
53.7%). The median (interquartile range) ICU-LOS was 7 
(3–14) days.
 Table 1 shows the characteristics of the study cohort 
based on the type of CRRT. Patients treated with 
Table 1. Characteristics of the study cohort, by type of CRRT
Variable AN69ST-CRRT Standard-only-CRRT p value
Total 156 2,322
Age, years, mean (SD) 70.4 (14.2) 70.3 (14) 0.88
Gender, male, n (%) 99 (63.5) 1,544 (66.5) 0.43
Type of admission (emergency), n (%) 119 (76.3) 1,676 (72.2) 0.31
Type of surgery, n (%)
Noninvasive abdominal 6 (3.9) 68 (2.9) 0.47
Invasive abdominal 51 (32.7) 453 (19.5) <0.0005
Cardiac 34 (21.8) 681 (29.3) 0.04
CCI, score, mean (SD) 2.13 (2.01) 2.29 (2.05) 0.25
AKI, n (%) 121 (77.6) 1,814 (78.1) 0.84
DIC, n (%) 99 (63.5) 1,067 (46) <0.0005
Sepsis, n (%) 100 (64.1) 1,096 (47.2) <0.0005
Vasopressors number, mean (SD) 2.0 (1.0) 1.7 (1.2) 0.01
Infusions, n (%)
Plat/FFP 87 (55.8) 1,194 (51.4) 0.32
RBC 89 (57.1) 1,252 (53.9) 0.46
Mechanical ventilation, n (%) 136 (87.2) 1,740 (74.9) <0.0005
Death, n (%)
In ICU 35 (22.4) 624 (26.9) 0.26
In hospital 78 (50.0) 1,253 (54.0) 0.36
ICU LOS, days, median (IQR) 7 (2–14) 7 (3–14)
AKI, acute kidney injury; CCI, Charlson Comorbidity Index; CRRT, continuous renal replacement therapy; 
DIC, disseminated intravascular coagulation; FFP, fresh frozen plasma; ICU LOS, intensive care unit length of 
stay; RBC, red blood cell.
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 AN69ST-CRRT had a significantly higher probability for 
open abdominal surgery, DIC, and sepsis diagnoses, and 
with a significantly greater degree of ventilator and vaso-
pressor support. Crude ICU mortality was 22.4 vs. 26.9% 
( p = 0.26), and crude in-hospital mortality was 50.0 vs. 
54.0% ( p = 0.36) in the AN69ST-CRRT and standard-on-
ly-CRRT groups, respectively.
 Main Results 
 The fully adjusted main effects from the logistic re-
gression model for hospital mortality are illustrated in 
 Figure 1 . The following variables were omitted from the 
model due to 2-tailed partial likelihood ratio test  p values 
>0.2 when jointly adjusted for other covariates: AKI, 
emergency versus elective surgery, hospital size, year of 
admission, and gender. In the final mortality model, 
 AN69ST-CRRT was associated with a statistically signifi-
cant lower mortality risk than standard-only-CRRT (OR 
95% CI 0.65 [0.45–0.93]), fully adjusted for the covariates 
( Table 1 ).
 The fully adjusted main effects from the generalized 
linear model for ICU-LOS log link are illustrated in 
 Figure 2 . The following variables were omitted from the 
model due to 2-tailed partial likelihood ratio test  p val-
ues >0.2 when jointly adjusted for other covariates: in-
vasive and noninvasive abdominal surgery; emergency 
versus elective surgery, CCI, number of vasopressors, 
year of admission, and gender. AN69ST-CRRT was as-
sociated with a statistically nonsignificant trend to 
shorter ICU-LOS than standard-only-CRRT with a rel-
ative risk (RR) of 0.91 (0.81–1.02). However, ICU 
death was a strong and significant predictor of shorter 
ICU-LOS with an RR of 0.62 (0.58–0.66), suggesting 
that ICU-LOS is better modeled as 2 competing risks: 
“ICU discharge without death”, vs. “death at ICU dis-
charge”.
 The cumulative incidence of ICU discharge without 
death is shown in  Figure 3 . We observed a step-up of cu-
mulative incidence of ICU discharge at day 14. This is 
probably because of the Japanese reimbursement system 
in which ICU management fee is covered up to 14 days. 
The fully adjusted main effects from the competing risks 
model for “ICU discharge without death” are illustrated 
in  Figure 4 . The following variables were omitted from 
the model due to 2-tailed partial likelihood ratio test  p 
values >0.2 when jointly adjusted for other covariates: 
sepsis, age, albumin infusion, CCI, cardiac surgery, red 
blood cell infusion, year of admission, and gender. 
 AN69ST-CRRT was associated with a statistically signifi-
cant greater probability of “ICU discharge without death,” 
with a SHR of 1.23 (1.03–1.50). Accounting for the com-
peting risk of death at ICU discharge, the median ICU-
LOS can be estimated from the cumulative incidence 
function, and was 11 days for the AN69ST-CRRT group 
and 13 days for the standard-only-CRRT group (median 
ICU LOS ratio 1.18).
AN69ST-CRRT vs. standard-only-CRRT
Hospital DPC III vs. DPC I/II
Mechanical ventilation
Albumin infusion
RBC transfusion
Platelet or FFP infusion
?2 vasopressor
1 vasopressor
Emergency vs. elective admission
Cardiac surgery
Invasive abdominal surgery
Sepsis
DIC
Charlson co-morbidity index >1
Age, years
0.5 1.0 1.5 2.0 2.5 3.0
OR, hospital death
 Fig. 1. Fully adjusted main effects from the 
logistic regression model for hospital mor-
tality. DIC, disseminated intravascular co-
agulation; FFP, fresh frozen plasma; RBC, 
red blood cell; DPC, diagnosis procedure 
combination; CRRT, continuous renal re-
placement therapy; OR, odds ratio. 
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 Other Results 
 Although no effect modification by AKI diagnosis was 
observed in the mortality model ( p = 0.132), there was sta-
tistically significant effect modification by sepsis diagnosis 
( p = 0.012), with a slightly lower point estimate for 
 AN69ST-CRRT versus standard-only-CRRT in those 
without sepsis (OR 0.53 [0.28–1.02]) compared to those 
with sepsis (0.73 [0.46–1.16]). There was significant effect 
modification by AKI diagnosis in the generalized linear 
model of ICU-LOS ( p = 0.037), with a slightly lower point 
estimate for AN69ST-CRRT versus standard-only-CRRT 
in those with AKI (RR 0.84 [0.66–1.06]) compared to those 
without AKI (0.93 [0.82–1.06]). There was no significant 
effect modification by AKI or sepsis diagnosis in the com-
peting risks ICU-LOS model. In all interaction models, CIs 
are wide as the result of the halved sample sizes.
 Table 2 summarizes the results of our sensitivity anal-
yses for unmeasured confounding. Only adjustment for a 
strong confounder (e.g., one that produces a >3–10 fold 
decrease in risk of death) resulted in the attenuation of the 
association between type of CRRT and mortality risk. Ad-
justment for more moderate confounding produced little 
change in the results. These results suggest that the asso-
ciations for AN69ST-CRRT versus standard-only-CRRT 
are unlikely to have been due to confounding only.
 Discussion 
 Severe AKI that requires CRRT, especially complicat-
ed with sepsis, shows unacceptably high mortality rates 
 [39] . In our study, the ICU and hospital mortality of our 
patients were 22.4 and 26.9%, respectively. These mortal-
ity rates are somewhat lower than the previous reports 
from other countries possibly because of region-specific 
reasons (e.g., proportion of respiratory support in ICU 
AN69ST-CRRT vs. standard-only-CRRT
AKI
Hospital >500 beds
Hospital 200–500 beds
Hospital DPC III vs. DPC I/II
Mechanical ventilation
Albumin infusion
RBC transfusion
Platelet or FFP infusion
Emergency vs. elective admission
Cardiac surgery
Sepsis
DIC
Age, years
ICU death
0.6 0.8 1.0 1.2 1.4 1.6
Relative risk, ICU-LOS
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cu
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0 10 20 30 40
Time to discharge, days
Standard-only-CRRT
AN69ST-CRRT
 Fig. 2. Fully adjusted main effects from the 
generalized linear model for intensive care 
unit length of stay (ICU-LOS). DIC, dis-
seminated intravascular coagulation; AKI, 
acute kidney injury; FFP, fresh frozen plas-
ma; RBC, red blood cell; DPC, diagnosis 
procedure combination; CRRT, continu-
ous renal replacement therapy. 
 Fig. 3. Cumulative incidence plot of ICU discharge without death. 
ICU, intensive care unit. 
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patients is lower in Japan than other countries). Of note, 
the mortality rates in this study are similar to other re-
ports on septic ICU patients treated in Japan  [40] .
 Although CRRT with any currently available mem-
brane can control uremia sufficiently, additive therapeu-
tic effects beyond renal replacement might improve the 
outcomes of these severely ill patients. Several mem-
branes that have high capability of adsorption including 
AN69ST are expected to remove the middle-size mole-
cules of inflammatory humoral mediators. In this study, 
AN69ST-CRRT vs. standard-only-CRRT
Hospital >500 beds
Hospital ?200 and <500 beds
Mechanical ventilation
Albumin infusion
Platelet or FFP infusion
?2 vasopressors
1 vasopressor
Emergency vs. elective admission
Cardiac surgery
Invasive abdominal surgery
Emergency surgery
DIC
0.5 1.0 1.5 2.0
Subhazard ratio for ICU discharge without death
 Fig. 4. Fully adjusted main effects from the 
competing risk model for intensive care 
unit length of stay (ICU-LOS), accounting 
for competing risk of ICU death. DIC, dis-
seminated intravascular coagulation; AKI, 
acute kidney injury; FFP, fresh frozen plas-
ma; DPC, diagnosis procedure combina-
tion; CRRT, continuous renal replacement 
therapy. 
Table 2.  Sensitivity of HRs for the association between AN69ST-CRRT and mortality risk (relative to standard-only-CRRT), adjusted 
for unmeasured confounding
p1 p0  HRCD
0.9 0.7 0.5 0.3 0.1
0.65 0.2 0.81 0.76 0.87 1.03 1.28
0.6 0.25 0.77 0.73 0.81 0.92 1.10
0.55 0.3 0.73 0.71 0.76 0.83 0.94
0.5 0.35 0.70 0.68 0.72 0.76 0.81
0.45 0.4 0.67 0.66 0.67 0.68 0.70
0.4 0.45 0.63 0.64 0.63 0.62 0.60
0.35 0.5 0.60 0.62 0.59 0.56 0.52
0.3 0.55 0.58 0.60 0.55 0.51 0.45
0.25 0.6 0.55 0.58 0.52 0.46 0.39
0.2 0.65 0.52 0.56 0.49 0.41 0.33
 HRs are computed as point estimates only. The base model assumes an HR of 0.65, adjusted for known confounders, when unmea-
sured confounders are present but unaccounted for. When an unmeasured confounder of varying strength and prevalence is introduced 
into the models, the hazard ratios are only sensitive to strong unmeasured confounding, with an effect that remains after adjustment for 
only weak-moderate confounding.
HRs, hazard ratios; CRRT, continuous renal replacement therapy; HRCD, hazard ratio for the association between unmeasured con-
founder and mortality risk; p1, prevalence of unmeasured confounder among those on AN69ST-CRRT; p0, prevalence of unmeasured 
confounder among those on to standard-only-CRRT.
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with an anonymized large claim-based database, the use 
of AN69ST membrane was significantly associated with 
lower in-hospital mortality (adjusted OR of 0.65, 95% CI 
0.45–0.93) and shorter ICU-LOS among patients receiv-
ing CRRT in Japanese ICUs.
 Hypercytokinemia is observed in a variety of serious 
conditions in ICU patients, including sepsis, trauma, 
pancreatitis, and burns, and plays a key role in the inflam-
mation cascade  [41] . In particular, plasma cytokine levels 
such as IL-6 and high-mobility group protein B1 are in-
creased with impaired kidney function  [42–45] . There-
fore, removing cytokines in addition to renal replacement 
seems a plausible intervention to reduce the maladaptive 
inflammation cascade in sepsis. AN69ST membrane has 
been shown to have a high capacity to adsorb cytokines 
(tumor necrosis factor-α, IL-1β, IL-6, and IL1ra) and 
HMGM1 in vitro experiments  [46, 47] .
 However, only one clinical study by Shiga et al.  [48], 
 which evaluated AN69ST-CRRT has been reported so far. 
A prospective multicenter study demonstrated that the 28-
day survival of 34 patients receiving AN69ST-CRRT was 
73.5%, which was higher than the predicted 28-day survival 
of 20.3% based on their severity at ICU admission (Acute 
Physiology and Chronic Health Evaluation II score 32.7 ± 
9.8). Because the study by Shiga et al.  [48]  was a single-arm 
study, there was no control group using other CRRT mem-
branes. AN69ST membrane was approved by the National 
Health Insurance System in Japan since 2014. Therefore, 
analyzing the claim data for AN69ST use in our study en-
ables us to examine the real-world effectiveness of AN69ST-
CRRT in comparison with other CRRT membranes.
 The information obtained from the Japanese claim da-
tabase revealed that the patients in the AN69ST-CRRT 
group were more likely to receive larger number of vaso-
pressors and mechanical ventilator support than those in 
the standard-only-CRRT group, suggesting that AN69ST 
membrane was preferentially used for patients in a more 
severe condition. After adjusting for differences includ-
ing severity, the use of AN69ST was significantly associ-
ated with a lower in-hospital mortality with adjusted OR 
of 0.65 (95% CI 0.45–0.93). Although no data regarding 
blood cytokine concentrations were available in this 
study, better control of humoral mediators achieved by 
AN69ST might contribute to the favorable use of this 
membrane for higher survival rate.
 We also compared ICU-LOS between the AN69ST-
CRRT and standard-only-CRRT groups, as early dis-
charge from ICU is an indirect marker of patients’ im-
proved conditions. This outcome is also important in 
terms of cost effectiveness and hospital resource utiliza-
tion. Because crude ICU mortality was lower in the 
 AN69ST-CRRT group than the standard-only-CRRT 
group (22.4 vs. 26.9%), we took into account the compet-
ing risk (i.e., early death leads to early discharge from 
ICU) in our statistical analysis. As a result, the use of the 
AN69ST membrane was also independently associated 
with shorter ICU-LOS. This result may suggest that 
 AN69ST-CRRT not only improved survival rate but also 
enhanced early recovery from a severe condition.
 There are several limitations in our study. First, there 
may be a selection bias of participating hospitals because 
the Medical Data Vision’s database consists of hospitals 
voluntarily contributing to the company, and there is no 
detailed information on how different these hospitals and 
other Japanese hospitals are in terms of patient character-
istics and medical care including CRRT management. 
However, we acknowledge at least that demographics and 
crude in-hospital mortality of patients in the current study 
were similar to those of CRRT-treated patients (median 
age 72, male 66.0%, and in-hospital mortality of 50.6%) in 
a Japanese nationwide database consisting of around 
1,000 hospitals  [39]. Second, although we adjusted for a 
number of potential confounding factors in regression 
analyses, residual confounding cannot be fully removed in 
observational studies. Unmeasured confounding factors 
mainly include vital signs and laboratory results. Howev-
er, we were able to adjust for the use of vasopressors, me-
chanical ventilation, blood products and albumin, which 
are expected to reflect patients’ severity. Moreover, our 
sensitivity analysis suggested that current findings are un-
likely to be explained only by confounding, unless the lev-
el of confounding is very strong ( Table 2 ).
 Third, we used recorded diagnoses (ICD-10 and DPC 
codes) of sepsis, DIC, and AKI for confounding adjust-
ment and test for interaction (effect modification). How-
ever, recorded diagnoses of sepsis and DIC are known to 
have high specificity but low sensitivity in the Japanese 
claims system  [49] . This was similar in a US validation 
study of AKI diagnosis  [50], although there has been no 
validation study of AKI diagnosis in Japan. Misclassifica-
tion of disease diagnoses may make the interpretation of 
our interaction test difficult. More accurate classification 
of sepsis, DIC, and AKI status based on vital signs and lab-
oratory results would be necessary for identifying the best 
target group of this treatment in future studies. Finally, we 
were dependent on the classification of filters in the Japa-
nese claims data, which distinguish only  AN69ST mem-
branes from other filters by virtue of a different reimburse-
ment code. Our standard group included patients treated 
with polysulfone, cellulose, and PMMA membranes. Al-
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though evidence suggests that AN69ST might have slight-
ly greater adsorption of HMGB-1  [47] , AN69ST and 
PMMA are both classified as adsorptive membranes. Un-
fortunately, we cannot differentiate PMMA from other 
membranes in the standard group, since the reimburse-
ment is the same for all membranes other than AN6ST, and 
our study is based on claim records. We cannot estimate 
the proportion of patients treated with PMMA in the stan-
dard group, although the inclusion of PMMA membranes 
in this group would potentially reduce the observed and 
modeled benefit of  AN69ST in our study, if adsorption 
were truly effective. Therefore, the benefit of AN69ST ob-
served in this study might be underestimated.
 In conclusion, this retrospective observational study 
suggests that the use of AN69ST membrane might be as-
sociated with improved outcomes including in-hospital 
mortality and ICU-LOS among patients receiving CRRT 
in ICU. Further prospective studies including random-
ized control trials are warranted to confirm this finding 
and to better elucidate the clinical significance of cytokine 
removal in patients admitted to ICUs.
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